COMMUNIQUÉS West-GlobeNewswire
-
Radiant Health Centers Names Mark Gonzales Interim CEO Amid Period of Expansion
27/03/2026 -
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
27/03/2026 -
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
26/03/2026 -
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
26/03/2026 -
SIGA Declares Special Cash Dividend of $0.60 Per Share
26/03/2026 -
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026 -
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
26/03/2026 -
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
26/03/2026 -
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
26/03/2026 -
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
26/03/2026 -
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
26/03/2026 -
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
26/03/2026 -
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
26/03/2026 -
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2025 Financial Results on March 31, 2026
26/03/2026 -
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
26/03/2026 -
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
26/03/2026 -
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/03/2026 -
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026
26/03/2026 -
XORTX Announces Change of Effective Date of Share Consolidation
26/03/2026
Pages